-+ 0.00%
-+ 0.00%
-+ 0.00%

BioAge hosts R&D Day webcast on BGE-102 NLRP3 inhibitor program

PUBT·05/04/2026 20:39:17
Listen to the news
BioAge hosts R&D Day webcast on BGE-102 NLRP3 inhibitor program
  • BioAge Labs to host an R&D Day webcast on May 8, 2026, starting 12:30 PM ET, focused on NLRP3 inhibition.
  • Event set to feature Phase 1 clinical data for BGE-102, an oral NLRP3 inflammasome inhibitor.
  • Company to outline development rationale for BGE-102 in atherosclerotic cardiovascular disease, plus retinal disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bioage Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605041630PRIMZONEFULLFEED9712553) on May 04, 2026, and is solely responsible for the information contained therein.